| Establishment of the large-scale longitudinal multi-omics dataset in COVID-19 patients : Data Profile and Biospecimen |
| Hyun-Young Park9,* (Director in department of Precision Medicine), Hye-Yeong Jo1 (Staff Scientist), Sang Cheol Kim1 (Senior Staff Scientist), Do-hwan Ahn1 (Researcher), Siyoung Lee2 (Researcher), So-Young Jung3 (Researcher), Young-Jin Kim4 (Staff Scientist), Eugene Kim3 (Senior Staff Scientist), Jung-Eun Kim5 (Senior Staff Scientist), Yeon-Sook Kim6 (Professor), Woong-Yang Park2,7 (Professor), Nam-Hyuk Cho8 (Professor), Donghyun Park2 (Researcher), Ju-Hee Lee1 (Director in Division of Healthcare and Artificial Intelligence) |
1Division of Healthcare and Artificial Intelligence, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheong-Ju, South Korea,
2Geninus Inc, Seoul, South Korea,
3National Biobank of Korea, Department of Precision Medicine and 4Division of Genome Science, Department of Precision Medicine and 5Division of Bio bigdata, Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheong-Ju, South Korea,
6Division of Infectious Disease, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea,
7Samsung Genome Institute, Samsung Medical Center, Seoul, South Korea,
8Department of Microbiology and Immunology, College of Medicine, Seoul National University, Seoul, South Korea,
9Department of Precision Medicine, Korea National Institute of Health, Korea Disease Control and Prevention Agency, Cheong-Ju, South Korea |
|
Abstract
Understanding and monitoring virus-mediated infections has gained importance since the global outbreak of the coronavirus disease 2019 (COVID-19) pandemic. Studies of high-throughput omics-based immune profiling of COVID-19 patients can help manage the current pandemic and future virus-mediated pandemics. Although COVID-19 is being studied since past 2 years, detailed mechanisms of the initial induction of dynamic immune responses or the molecular mechanisms that characterize disease progression remains unclear. This study involved comprehensively collected biospecimens and longitudinal multi-omics data of 300 COVID-19 patients and 120 healthy controls, including whole genome sequencing (WGS), single-cell RNA sequencing combined with T cell receptor (TCR) and B cell receptor (BCR) sequencing (scRNA(+scTCR/BCR)-seq), bulk BCR and TCR sequencing (bulk TCR/BCR-seq), and cytokine profiling. Clinical data were also collected from hospitalized COVID-19 patients, and HLA typing, laboratory characteristics, and COVID-19 viral genome sequencing were performed during the initial diagnosis. The entire set of biospecimens and multi-omics data generated in this project can be accessed by researchers from the National Biobank of Korea with prior approval. This distribution of large-scale multi-omics data of COVID-19 patients can facilitate the understanding of biological crosstalk involved in COVID-19 infection and contribute to the development of potential methodologies for its diagnosis and treatment.
Keywords: COVID-19, Multi-omics, Immunology, Infection biology, Biobanking
|
| Abstract, Accepted Manuscript(in press) [Submitted on May 9, 2022, Accepted on July 29, 2022] |
|